Literature DB >> 16319029

Venous thrombosis in an ALS population over four years.

L B Elman1, A Siderowf, G Houseman, M Kelley, L F McCluskey.   

Abstract

We conducted a retrospective chart review of all ALS patients seen at our institution over four years to determine the incidence of venous thromboembolism and to identify risk factors in this population. Events occurred in 13 of 438 patients (2.97%), yielding an annual incidence rate of 33.1 events per 1,000 patients (95% CI 17.5-55.3). ALS patients have a risk of venous thromboembolism that is higher than the general population but lower than the population of patients with acute stroke or spinal cord injury. Immobility was significantly associated with increased risk of venous thrombosis (RR = 4.96; 95% CI 1.39-17.78).

Entities:  

Mesh:

Year:  2005        PMID: 16319029     DOI: 10.1080/14660820510043226

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord        ISSN: 1466-0822


  6 in total

1.  Transplantation of spinal cord-derived neural stem cells for ALS: Analysis of phase 1 and 2 trials.

Authors:  Jonathan D Glass; Vicki S Hertzberg; Nicholas M Boulis; Jonathan Riley; Thais Federici; Meraida Polak; Jane Bordeau; Christina Fournier; Karl Johe; Tom Hazel; Merit Cudkowicz; Nazem Atassi; Lawrence F Borges; Seward B Rutkove; Jayna Duell; Parag G Patil; Stephen A Goutman; Eva L Feldman
Journal:  Neurology       Date:  2016-06-29       Impact factor: 9.910

Review 2.  Management of respiratory symptoms in ALS.

Authors:  Orla Hardiman
Journal:  J Neurol       Date:  2010-11-17       Impact factor: 4.849

3.  Venous thromboembolism in amyotrophic lateral sclerosis: a prospective study.

Authors:  Matthew Gladman; Melanie Dehaan; Hanika Pinto; William Geerts; Lorne Zinman
Journal:  Neurology       Date:  2014-04-11       Impact factor: 9.910

4.  Subcutaneous IGF-1 is not beneficial in 2-year ALS trial.

Authors:  E J Sorenson; A J Windbank; J N Mandrekar; W R Bamlet; S H Appel; C Armon; P E Barkhaus; P Bosch; K Boylan; W S David; E Feldman; J Glass; L Gutmann; J Katz; W King; C A Luciano; L F McCluskey; S Nash; D S Newman; R M Pascuzzi; E Pioro; L J Sams; S Scelsa; E P Simpson; S H Subramony; E Tiryaki; C A Thornton
Journal:  Neurology       Date:  2008-11-25       Impact factor: 9.910

5.  Intracerebroventricular delivery of vascular endothelial growth factor in patients with amyotrophic lateral sclerosis, a phase I study.

Authors:  Philip Van Damme; Petra Tilkin; Katarina Jansson Mercer; Joke Terryn; Ann D'Hondt; Nina Herne; Thomas Tousseyn; Kristl G Claeys; Dietmar R Thal; Olof Zachrisson; Per Almqvist; Bart Nuttin; Markus Jerling; Folke Bernadotte; Anders Haegerstrand; Wim Robberecht
Journal:  Brain Commun       Date:  2020-09-29

6.  Safety and Efficacy of Allogeneic Adipose Tissue Mesenchymal Stromal Cells in Amyotrophic Lateral Sclerosis Patients, Single-Center, Prospective, Open-Label, Single-Arm Clinical Trial, Long-Term Follow-up.

Authors:  Seyed Massood Nabavi; S Hahedeh Karimi; Leila Arab; Leila Sanjari; Soura Mardpour; Vajiheh Azimian; Neda Jarughi; Azadeh Ghaheri; Seyedeh-Esmat Hosseini; Nasser Aghdami; Massoud Vosough
Journal:  Cell J       Date:  2021-12-29       Impact factor: 2.479

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.